You are here: Industry Insights > BCC

News List

New Information from NCCN on Most Common Type of Cancer; Diagnosed in Millions Every Year prnasia
October 14, 2021
The National Comprehensive Cancer Network (NCCN®) today announced the publication of new NCCN Guidelines for Patients® Basal Cell Skin Cancer (also known as basal cell carcinoma, or BCC), the most common form of skin cancer.
Remetinostat shows promise as a BCC treatment in Phase II study europeanpharmaceuticalreview
August 06, 2021
Remetinostat, a first-in-class histone deacetylase inhibitor gel, displayed signs of clinical efficacy in patients with basal cell carcinoma.
Sanofi, Regeneron's Libtayo cleared for basal cell carcinoma pharmatimes
June 28, 2021
Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) has won a green light in Europe as the first immunotherapy to treat adults with locally advanced or metastatic basal cell carcinoma (BCC).
First Patient Dosed in STP705 Study Cutaneous Basal Cell Carcinoma Treatment americanpharmaceuticalreview
January 27, 2021
Sirnaomics announced dose administration for the first patient in a Phase 2a clinical study of the company's lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma.
AiViva Biopharma Initiates Trial of AIV001 for Nonmelanoma Skin Cancer americanpharmaceuticalreview
October 12, 2020
AiViva Biopharma has begun dosing patients diagnosed with superficial or nodular basal cell carcinoma (BCC) with AIV001.
Thermo Fisher Scientific Opens New Bioprocessing Collaboration Center in St. Louis americanpharmaceuticalreview
September 15, 2020
Thermo Fisher Scientific has announced the opening of its new Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri.
Sanofi/Regeneron's Libtayo shows benefit in BCC pharmatimes
May 08, 2020
Sanofi and Regeneron's Libtayo (cemiplimab) has demonstrated 'clinically meaningful and durable responses' in a subset of patients with basal call carcinoma (BCC) from whom there are currently no approved treatments.